

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING D	ATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/853,253	05/10/20	001	Stephen R. Jaspers	00-30	5039
7	7590 1	12/31/2002			
Robyn Adam		EXAMINER PAK, YONG D			
ZymoGenetics 1201 Eastlake	Avenue East				
Seattle, WA 98102				ART UNIT	PAPER NUMBER
				1652	
				DATE MAILED: 12/31/2002	9

Please find below and/or attached an Office communication concerning this application or proceeding.

_^							
Office Action Summary		Application No.	Applicant(s)				
		09/853,253	JASPERS ET AL.				
		Examiner	Art Unit				
		Yong Pak	1652				
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
THE N - Exten after S - If the - If NO - Failur - Any re	DRTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. sions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period we to reply within the set or extended period for reply will, by statute, apply received by the Office later than three months after the mailing d patent term adjustment. See 37 CFR 1.704(b).	66(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) day fill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
1)⊠	Responsive to communication(s) filed on 25 N	lovember 2002 .					
2a) <u></u> □	This action is FINAL . 2b)⊠ Thi	s action is non-final.					
3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)🖾	4)⊠ Claim(s) 1,3,5,7 and 9 is/are pending in the application.						
4a) Of the above claim(s) <u>3,5,7 and 9</u> is/are withdrawn from consideration.							
5)[Claim(s) is/are allowed.						
6)⊠	6) Claim(s) 1 is/are rejected.						
7)	Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.							
	on Papers						
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) <u>6</u>	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)				
I.S. Patent and Tr	ademark Office						

Application/Control Number: 09/853,253

Art Unit: 1652

DETAILED ACTION

The amendment filed November 25, 2002, canceling claims 2, 4, 6, 8 and 10, has been entered.

Claims 1, 3, 5, 7 and 9 are pending.

Election/Restrictions

Applicant's election with traverse of Group I with a further election of SEQ ID NO:4 in Paper No. 7 is acknowledged. The traversal is on the ground(s) that the various polypeptides are all related because they are fragments of a longer polypeptide or that some of the polypeptides are modifications of the fragments of the longer polypeptide. SEQ ID NO:5-6 will be examined with SEQ ID NO:4, but SEQ ID NO:9 (with SEQ ID NO:10-11), SEQ ID NO:14 (with SEQ ID NO:15-16), SEQ ID NO:20 (with SEQ ID NO:21-22) and SEQ ID NO:25 (with SEQ ID NO:26) remain as patentably distinct inventions because they have different structure and have different substrate specificity.

The requirement is still deemed proper and is therefore made FINAL.

Claims 3, 5, 7 and 9 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 7.

Application/Control Number: 09/853,253

Art Unit: 1652

ì

Specification

The sequence Rules 1.821 (c) requires <u>a</u> sequence identifier for each sequences. However, the same amino acid sequence is identified by different sequence identifiers, SEQ ID NOs: 5 and 6 (see Sequence Listing, pages 3-4).

Claim Rejections - 35 USC § 102

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by Sheppard et al.

Sheppard et al. (WO 98/42840) teach a polypeptide comprising SEQ ID NO:4 of the instant invention (SEQ ID NO:2, pages 55-56). Therefore, the reference of Sheppard et al. anticipates claim 1

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong Pak whose telephone number is 703-308-9363. The examiner can normally be reached on 8:00 A.M. to 4:30 P.M weekdays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 703-308-3804. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

PONNATHAPUACHUTAMURTHY

SUPERMENTAL TOTAL TEXAMINER

Yong Pak Patent Examiner December 18, 2002